Tumor Organoids Preclinical Models Dream Team - Stand Up To Cancer

Dream Teams

Research  >  Research Portfolio  >  Dream Teams  >  Tumor Organoids Preclinical Models Dream Team

SU2C–Dutch Cancer Society
Tumor Organoids Dream Team:
A New Preclinical Model for Drug Sensitivity Analysis

Grant Term: April 2014–April 2019

The SU2C–Dutch Cancer Society (DCS) Tumor Organoids Dream Team has developed a groundbreaking technology that allows oncology samples from patients to be maintained and grown in the laboratory. These growing cancers, called tumor organoids, provide an unprecedented opportunity to combine science’s ability to sequence the DNA of tumors from individual patients with laboratory studies to see if the cancer will respond to or resist specific anticancer treatments. The organoids allow studies of sensitivity and resistance to a large number of anticancer drugs, ultimately helping doctors bring better and more targeted treatments to cancer patients.

ABOUT THIS TEAM’S RESEARCH

The promise of precision medicine lies in the ability of researchers to devise treatments that are specific to the genetic profile of individual patients and their tumors. However, predicting which drug or drug combination will be the most effective based on the genetic makeup of a tumor remains a challenge.

In order to investigate the consequences of all the DNA changes that contribute to cancer progression, and how those changes can be targeted by drugs, this SU2C–DCS Tumor Organoids Dream Team has developed a groundbreaking technology that allows tumor samples isolated from patients to be maintained and grown in a laboratory setting as “tumor organoids.”

Importantly, these tumor organoids will allow studies of sensitivity and resistance to a large number of anticancer drugs in the lab. The ultimate goal is to design new and more sophisticated clinical trials that test treatment regimens tailored to a patient’s tumor. If successful, this Dream Team project has the potential to provide a true paradigm shift in our current approach to drug development, clinical trial design, and therapy, ultimately providing effective new targeted treatment options for cancer patients.

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.